Heterocyclic compound
AssigneeTakeda Pharmaceutical Company Limited
InventorsMasahiro Ito, Hideyuki Sugiyama, Takeshi Yamamoto, Keiko Kakegawa, Jinxing Li, Junsi Wang, Takahito Kasahara, Masato Yoshikawa
Life of this patent
Estimating the term…
Abstract
The present invention provides a heterocyclic compound having a HDAC6 inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
Claims2
A method of inhibiting histone deacetylase 6 in a mammal, which comprises administering to the mammal an effective amount of a compound represented by formula (I) or a salt thereof:
- wherein R1 is an optionally substituted cyclic group, and R2 is an optionally substituted cyclic group.
A method for treatment of Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia and parkinsonism linked to MAPT mutation (FTDP-17), frontotemporal dementia, Charcot-Marie-Tooth disease, peripheral neuropathy, amyotrophic lateral sclerosis (ALS) or cancer in a mammal, which comprises administering to the mammal an effective amount of a compound represented by formula (I) or a salt thereof:
- wherein R1 is an optionally substituted cyclic group, and R2 is an optionally substituted cyclic group.
Dependencies are inferred from the claim text.